Epigenomics of Breast Cancer

Our research focuses on understanding how breast cancer cells respond and adapt to treatment, with particular emphasis on the role of epigenetic and transcriptional regulation in endocrine resistance. We use large-scale multi-omics data, including single-cell analyses, to identify regulatory mechanisms that enable cancer cells to survive treatment and develop resistance. By combining computational approaches with functional experiments, including CRISPR-based epigenetic editing, gene perturbation, and in vitro drug testing, we investigate the causal roles of regulatory mechanisms in treatment response and resistance. Ultimately, our goal is to uncover new therapeutic vulnerabilities that can be exploited to overcome resistance and identify biomarkers of treatment response.
Contact information
Key publications
- Ankill J, ..., Fleischer T, Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation, PLOS Comp Biol 2024, Pubmed 39556603
- Brativnyk A, ..., Fleischer T, Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma, Int J Cancer 2024, PubMed 38489486
- Fleischer T, ..., Engebraaten O, Kristensen VN, An integrated ‘omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab, Mol Oncol 2024, PubMed 38671580
- Ankill J, ..., Fleischer T, Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer, NAR Cancer 2022, PubMed 35350772
- Fleischer T*, Tekpli X*, ..., Kristensen VN, DNA methylation at enhancers identifies distinct breast cancer lineages, Nat Commun 2017, PubMed 29123100
- Fleischer T, ..., Kristensen VN (2014), Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis, Genome Biol 2014, PubMed 25146004